A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, ...

Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess casdatifan plus volrustomig for renal ...

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 ...

The following is a summary of “Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into ...

A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic ...